サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1795369

安定同位体標識生体分子の世界市場

Stable Isotope Labeled Biomolecules

出版日
ページ情報
英文 169 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
安定同位体標識生体分子の世界市場
出版日: 2025年08月21日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 169 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

安定同位体標識生体分子の世界市場は2030年までに5億1,700万米ドルに達する見込み

2024年に3億7,110万米ドルと推定される安定同位体標識生体分子の世界市場は、2030年には5億1,700万米ドルに達し、分析期間2024-2030年のCAGRは5.7%で成長すると予測されます。D標識生体分子は、本レポートで分析したセグメントの1つであり、CAGRは5.4%を記録し、分析期間終了時には3億800万米ドルに達すると予測されています。15N標識生体分子セグメントの成長率は、分析期間中CAGR 6.6%と推定されます。

米国市場は9,760万米ドルと推定、中国はCAGR5.5%で成長予測

米国の安定同位体標識生体分子市場は、2024年に9,760万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに8,290万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.0％と4.9％と予測されています。欧州では、ドイツがCAGR 4.6%で成長すると予測されています。

世界の安定同位体標識生体分子市場- 主要動向と促進要因のまとめ

調査用安定同位体標識生体分子の成長を牽引しているのは？

安定同位体標識生体分子は、13C、15N、2H標識アミノ酸、ヌクレオチド、脂質、代謝物など、プロテオミクス、メタボロミクス、薬物動態学、トレーサー研究における重要なツールです。質量分析アッセイ、同位体希釈定量、MRIイメージング剤、細胞トレーシング実験、代謝フラックス分析に使用されます。主なエンドユーザーは、学術研究所、製薬研究開発、バイオ製造QC、石油化学試験など。

正確な定量、経路マッピング、品質保証といった複雑なワークフローは、同位体の種類や標識部位によってカスタマイズされた高純度標識標準物質へのアクセスに依存しています。メーカーは、細胞培養への組み込み、内部標準化、イメージング・アプリケーション用に分子をカスタマイズします。LC-MS/MSとフラグメント分析における分析装置とソフトウェアの進歩は、堅牢な同位体標準物質への需要を高めています。

生産とカスタマイズのプラットフォームは可用性を高めているか？

企業は、高純度同位体を生産するために、生合成（標識された前駆体を用いた微生物発酵）、化学合成、酵素的生物変換の規模を拡大しています。新しいプラットフォームは、部位特異的標識や複数標識の組み合わせ（デュアル13C-15Nなど）をサポートし、きめ細かな代謝解析を可能にしています。フラッシュクロマトグラフィーやHPLCを用いた自動精製システムにより、スループットが向上し、コストが削減されます。

納期の最適化、つまり製薬会社のタイムラインに合わせた迅速なカスタムバッチは、デジタル注文ポータルやサンプル配送追跡によってサポートされています。薬物代謝試験や微生物フラックス評価用に調整されたマルチアイソトープキットは、CROやバイオメーカーでの利用を後押ししています。

なぜ研究者はこれらのツールを分野横断的に統合しているのか？

定量生物学者や薬理学者は、絶対濃度測定、クリアランスプロファイリング、薬物間相互作用研究に同位体標識標準物質を利用しています。システム生物学者は、標識前駆体を用いて天然産物の生合成経路を追跡しています。作物や環境の研究者は、土壌-植物系における取り込みや変換を追跡するために標識代謝物を使用します。臨床栄養学研究において、安定同位体液体トレーサーは吸収と代謝の運命を非侵襲的に追跡します。規制機関は、QCラボでのアッセイバリデーションやバッチリリーステストのために、標識された内部標準物質を必要としています。

安定同位体標識生体分子市場の成長の原動力は？

安定同位体標識生体分子市場の成長の原動力は、調査精度、生産スケーラビリティ、学際的採用に関するいくつかの要因です。発酵および化学標識法の進歩により、コストが削減され、複雑な同位体の利用可能性が拡大しています。プロテオミクス、メタボロミクス、医薬品パイプラインへの世界の投資の増加が、高品質標準物質への需要を支えています。カスタマイズされた短期合成やターンキー標準キットは、CRO、バイオファーマ、アカデミックのタイムラインを満たします。医薬品や食品安全アッセイにおける正確な定量に対する規制上の期待も、普及を後押ししています。さらに、装置ベンダーとアイソトープ・サプライヤー間のパートナーシップは、標識標準物質とサンプル前処理、分析、ソフトウェアを組み合わせた統合ワークフローを可能にし、結果までの時間と研究の質を加速します。

セグメント

タイプ（D標識生体分子、15N標識生体分子、13C標識生体分子）;エンドユーザー（科学研究、医療）

調査対象企業の例

  • Alsachim
  • BOC Sciences
  • Cambridge Isotope Laboratories
  • CDN Isotopes
  • Cerilliant Corporation
  • Entegris（IsoSciences）
  • Eurisotop
  • Ionetix
  • IsoFlex
  • IsoLife BV
  • JSC Isotope
  • LGC Standards
  • Lumiprobe
  • Medical Isotopes, Inc.
  • Merck KGaA（Sigma-Aldrich）
  • NIST
  • Nordion（Canada）, Inc.
  • Omicron Biochemicals, Inc.
  • PerkinElmer, Inc.
  • Silantes

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP38103

Global Stable Isotope Labeled Biomolecules Market to Reach US$517.0 Million by 2030

The global market for Stable Isotope Labeled Biomolecules estimated at US$371.1 Million in the year 2024, is expected to reach US$517.0 Million by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. D Labeled Biomolecules, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$308.0 Million by the end of the analysis period. Growth in the 15N Labeled Biomolecules segment is estimated at 6.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$97.6 Million While China is Forecast to Grow at 5.5% CAGR

The Stable Isotope Labeled Biomolecules market in the U.S. is estimated at US$97.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$82.9 Million by the year 2030 trailing a CAGR of 5.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.0% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Stable Isotope Labeled Biomolecules Market - Key Trends & Drivers Summarized

What’s Driving Growth in Stable Isotope Labeled Biomolecules for Research?

Stable isotope labeled biomolecules-such as ¹³C, ¹5N, ²H labeled amino acids, nucleotides, lipids, and metabolites-are critical tools in proteomics, metabolomics, pharmacokinetics, and tracer studies. Used in mass spectrometry assays, isotope dilution quantification, MRI imaging agents, cell tracing experiments, and metabolic flux analysis. Major end-users include academic labs, pharma R&D, biomanufacturing QC, and petrochemical testing.

Complex workflows-accurate quantification, pathway mapping, quality assurance-depend on access to high-purity labeled standards customized by isotope type and labeling sites. Manufacturers tailor molecules for cell-culture incorporation, internal standardization, and imaging applications. Analytical instrumentation and software advancements in LC-MS/MS and fragment analysis have elevated demand for robust isotopic standards.

Are Production & Customization Platforms Advancing Availability?

Companies are scaling biosynthesis (microbial fermentation with labeled precursors), chemical synthesis, and enzymatic biotransformations to produce high-purity isotopologues. New platforms support site-specific labeling and multiple-label combinations (e.g., dual ¹³C-¹5N), enabling fine-grained metabolic analysis. Automated purification systems using flash chromatography and HPLC increase throughput and reduce costs.

Turn-around optimization-rapid custom batches for pharma timelines-is supported by digital ordering portals and sample delivery tracking. Multi-isotope kits tailored for drug metabolism studies and microbial flux assessments are boosting usage in CROs and biomanufacturers.

Why Are Researchers Integrating These Tools Across Disciplines?

Quantitative biologists and pharmacologists rely on isotope-labeled standards for absolute concentration measurement, clearance profiling, and drug-drug interaction studies. Systems biologists track natural-product biosynthesis pathways using labeled precursors. Crop and environmental researchers use labeled metabolites to trace uptake and transformation in soil-plant systems. Stable isotope liquid tracers in clinical nutritional studies supply non-invasive tracking of absorption and metabolic fate. Regulatory bodies require labeled internal standards for assay validation and batch release tests in QC labs.

What’s Powering the Growth in the Stable Isotope Labeled Biomolecules Market?

The growth in the stable isotope labeled biomolecules market is driven by several factors related to research precision, production scalability, and interdisciplinary adoption. Advances in fermentation and chemical-labeling methods are reducing costs and expanding availability of complex isotopologues. Increasing global investment in proteomics, metabolomics, and drug pipelines supports demand for high-quality standards. Customized, short-run synthesis and turnkey standard kits meet CRO, biopharma, and academic timelines. Regulatory expectations for precise quantification in drug and food safety assays support widespread adoption. Additionally, partnerships between instrument vendors and isotope suppliers enable integrated workflows-combining labeled standards with sample prep, analytics, and software-accelerating time-to-result and research quality.

SCOPE OF STUDY:

The report analyzes the Stable Isotope Labeled Biomolecules market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (D Labeled Biomolecules, 15N Labeled Biomolecules, 13C Labeled Biomolecules); End-Use (Scientific Research End-Use, Medical End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 37 Featured) -

  • Alsachim
  • BOC Sciences
  • Cambridge Isotope Laboratories
  • CDN Isotopes
  • Cerilliant Corporation
  • Entegris (IsoSciences)
  • Eurisotop
  • Ionetix
  • IsoFlex
  • IsoLife BV
  • JSC Isotope
  • LGC Standards
  • Lumiprobe
  • Medical Isotopes, Inc.
  • Merck KGaA (Sigma-Aldrich)
  • NIST
  • Nordion (Canada), Inc.
  • Omicron Biochemicals, Inc.
  • PerkinElmer, Inc.
  • Silantes

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Stable Isotope Labeled Biomolecules - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growth in Proteomics and Metabolomics Research Drives Demand for Labeled Biomolecules
    • Rising Adoption of Mass Spectrometry in Life Sciences Propels Use of Stable Isotopes
    • Personalized Medicine and Targeted Drug Development Expand Addressable Research Applications
    • Regulatory Emphasis on Quantitative Bioanalysis Strengthens Business Case for Labeled Standards
    • Increase in Biopharma R&D Budgets Accelerates Demand for High-Purity Stable Isotope Compounds
    • Expansion of Clinical Diagnostics and Biomarker Discovery Spurs Usage in Preclinical Studies
    • Growth in Academic-Industry Collaborations Facilitates Commercial Availability of Custom Molecules
    • Technological Advancements in Labeling Techniques Improve Accuracy and Yield
    • Adoption of Isotope Dilution Techniques in Environmental and Food Testing Broadens Market Scope
    • Outsourcing Trends in Drug Discovery Boost Demand for Third-Party Stable Isotope Services
    • Rising Complexity of Biotherapeutics Drives Requirement for Multi-Isotopic Labeling
    • Globalization of CROs and CDMOs Expands Supply Chain for Labeled Biomolecule Manufacturing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Stable Isotope Labeled Biomolecules Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Stable Isotope Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Stable Isotope Labeled Biomolecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for D Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for D Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for D Labeled Biomolecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for 15N Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for 15N Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for 15N Labeled Biomolecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for 13C Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for 13C Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for 13C Labeled Biomolecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Scientific Research End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Scientific Research End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Scientific Research End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Medical End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Medical End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Medical End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Stable Isotope Labeled Biomolecules by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Stable Isotope Labeled Biomolecules by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Rest of Europe 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Rest of Europe 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Asia-Pacific 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Asia-Pacific 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • REST OF WORLD
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of World 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of World 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION